CLOs on the Move

ALung Technologies

www.alung.com

 
ALung Technologies has developed the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation. The Hemolung RAS provides Respiratory Dialysis,a simple, less invasive form of extracorporeal CO2 removal. By removing carbon dioxide and delivering oxygen directly to the blood, the Hemolung RAS allows the patients lungs to rest and heal. Applications of the device include preventing intubation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and enabling ultra-protective ventilation in acute respiratory distress syndrome (ARDS).
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million
  • www.alung.com
  • 2500 Jane St Ste 1
    Pittsburgh, PA USA 15203
  • Phone: 412.697.3370

Executives

Name Title Contact Details

Similar Companies

Amedica

Amedica Corporation is ISO 13485 certified, and its products are FDA and CE approved. Amedica Corporation is an emerging orthopaedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, unique spine and total joint implants for the growing orthopaedic device market.

TouchPointCare

TouchPointCare is a Libertyville, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Smith and Nephew

Smith & Nephew is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeStyles Condoms

LifeStyles Condoms is a Red Bank, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Miromatrix Medical

The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.